2Joseph J, A1-Qaisieh B, Ash D, et al. Prostate-specific antigenrelapse-free survival in patients with localized prostate cancertreated by brachytherapy. BJUlnt 2004; 94(9): 1235-1238.
3Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical(prostate-specific antigen) control of prostate cancer with (125)I brachytherapy, lnt J Radiat Oncol Biol Phys 2001; 51(1): 31-40.
4Zelefsky MJ, Hollister T, RabenA, et al. Five-year bioehemicaloutcome and toxicity with transperineal CT- planned perma_nentI- 125 prostate implantation for patients with localized prostate cancer, lnt J Raa'at Onto1 Biol Phys 2000; 47(5): 1261-1266.
5Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin 0nco12004; 22(11): 2141-2149.
6Merrick GS,Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003; 169(5): 1643 - 1652.
7Elshaikh MA, Angermeier K, Ulchaker JC, et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 2003; 61(1): 152-155.
8Celebrezze JP Jr, Medich DS. Rectal ulceration as a result of prostatic brachytherapy: A new clinical problem. Dis Colon Rectum 2003; 46(9): 1277-1279.
9Lamb MN, Trabinino L, Hackford A. Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer. Dis Colon Rectum 2011; 54(5): 615-621.
10Salem N, Simonian-Sauve M, RoselloR, et al. Preditive factors of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: a phase 2 study. Raakbther Oncol 2003; 66(2): 159-165.
2Segi M. Cancer mortality for selected sites in 24 countries(1950-57 ) [ M ]. Japan : Department of Public Health,Tohoku Univer-sity of Medicine, 1960.
3FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burdenof cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010,127(12) : 2893 -2917.
4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin’2011,61(2) :69 -90.
5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J].CA Cancer J Clin,2012,62( 1) :10 - 29.
